Abstract
BACKGROUND: Neoadjuvant chemoimmunotherapy (NCIT) has emerged as a promising approach for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, the risk of immune-related adverse events (irAEs) should be taken seriously. And subsequent treatment strategies are determined on the basis of the neoadjuvant effect. Therefore, identifying a robust and effective method to recognize sensitive patients and monitor treatment response is highly important. The study investigated the ability of texture analysis of MRI to predict treatment response after NCIT in patients with LA-HNSCC, and compared it with several clinical indicators. METHODS: This retrospective study included 49 LA-HNSCC patients who received NCIT followed by surgery. Texture features were extracted from MR images taken before and after NCIT. Delta features were defined as the percentage change from pre- to posttreatment features. Features that were significantly different between the pathological complete response (pCR) and non pCR groups were selected. Then the features with high diagnostic efficiency and low correlation were subsequently included in logistic regression analysis. Various diagnostic models were constructed via logistic regression, support vector machine (SVM), random forest (RF), and AdaBoost. Several clinical indicators, including tumor stage, combined positive score (CPS) derived from pretreatment lesions, and RECIST 1.1 evaluations by clinicians, were analyzed. ROC analysis and the Delong test were used to assess the performance of various models. RESULTS: A total of 24 (49.0%) patients achieved pCR, and 25 (51.0%) did not. The Pre_model, Post_model, and Delta_model demonstrated AUCs of 0.678, 0.795, and 0.805, respectively. Compared with the T stage (AUC 0.635), CPS (AUC 0.576), and RECIST1.1 criteria (AUC 0.670) (all p < 0.005), the Combined_model showed better performance, with an AUC of 0.868, a F1-score of 0.824. CONCLUSION: Texture analysis based on pre- and posttreatment MR images outperformed the T stage, CPS, and RECIST 1.1 criteria in predicting pathological response following NCIT in patients with LA-HNSCC. CLINICAL TRIAL NUMBER: Not applicable.